BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38250731)

  • 1. Prognostic significance of integrating total metabolic tumor volume and EGFR mutation status in patients with lung adenocarcinoma.
    Jiang M; Guo X; Chen P; Zhang X; Gao Q; Zhang J; Zheng J
    PeerJ; 2024; 12():e16807. PubMed ID: 38250731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Semiquantitative parameters of
    Liao XH; Wang RF; Liu M; Chen XQ; Xiong Y; Nong L; Yin L; Zhang BY; DU YJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 53(2):246-254. PubMed ID: 33879893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Xu HQ; Song LJ; Ding CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.
    Wang D; Zhang M; Gao X; Yu L
    PLoS One; 2016; 11(6):e0158307. PubMed ID: 27336755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Values of Baseline
    Zhou Y; Zhang X; Qin H; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S
    Biomed Res Int; 2020; 2020():9746716. PubMed ID: 32185229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
    Yanarateş A; Yazici B
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
    Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
    Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total metabolic tumor volume on
    Tricarico P; Chardin D; Martin N; Contu S; Hugonnet F; Otto J; Humbert O
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38649279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of total metabolic tumour volume and therapy-response assessment by [
    Annovazzi A; Ferraresi V; Rea S; Russillo M; Renna D; Carpano S; Sciuto R
    Eur Radiol; 2022 May; 32(5):3398-3407. PubMed ID: 34779873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma.
    Feng X; Wen X; Li L; Sun Z; Li X; Zhang L; Wu J; Fu X; Wang X; Yu H; Ma X; Zhang X; Xie X; Han X; Zhang M
    Cancer Res Treat; 2021 Jul; 53(3):837-846. PubMed ID: 33285054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluate the value of (18)F-FDG PET-CT imaging in predicting the mutationsin epidermal growth factor receptor in lung adenocarcinoma].
    Ding CY; Yang WP; Guo Z; Sun J; Li YY; Li TR
    Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):528-531. PubMed ID: 28728300
    [No Abstract]   [Full Text] [Related]  

  • 13. Primary metabolic tumor volume from 18F-FDG PET/CT associated with epidermal growth factor receptor mutation in lung adenocarcinoma patients.
    Liao X; Cui Y; Chen X; Di L; Tong Z; Liu M; Wang R
    Nucl Med Commun; 2020 Nov; 41(11):1210-1217. PubMed ID: 32815896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.
    Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of
    Geng H; Lian K; Zhang W
    Quant Imaging Med Surg; 2024 Jan; 14(1):325-334. PubMed ID: 38223089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of intratumor metabolic and heterogeneity parameters on [
    Ni M; Wang S; Liu X; Shi Q; Zhu X; Zhang Y; Xie Q; Lv W
    Jpn J Radiol; 2023 Feb; 41(2):209-218. PubMed ID: 36219311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic tumor burden on baseline
    Chen S; He K; Feng F; Wang S; Yin Y; Fu H; Wang H
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1830-1839. PubMed ID: 31187163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of EGFR Mutation Status to Metabolic Activity in Localized Lung Adenocarcinoma and Its Influence on the Use of FDG PET/CT Parameters in Prognosis.
    Kim YI; Paeng JC; Park YS; Cheon GJ; Lee DS; Chung JK; Kang KW
    AJR Am J Roentgenol; 2018 Jun; 210(6):1346-1351. PubMed ID: 29547059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.
    Toledano MN; Desbordes P; Banjar A; Gardin I; Vera P; Ruminy P; Jardin F; Tilly H; Becker S
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):680-688. PubMed ID: 29344718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between EGFR mutation status and F
    Zhu L; Yin G; Chen W; Li X; Yu X; Zhu X; Jiang W; Jia C; Chen P; Zhang Y; Lu D; Yu L; Li X; Xu W
    Thorac Cancer; 2019 Apr; 10(4):659-664. PubMed ID: 30776196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.